McKesson Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

How The Evolving Story On McKesson (MCK) Is Shaping Its Valuation Outlook

AI-generated analysis

πŸ“‰ McKesson's fair value estimate was reduced from US$990.87 to US$951.73, representing a 4% decrease.

βš–οΈ Analyst sentiment is mixed, with some firms raising targets while others are cutting price targets or placing the stock underperform.

πŸ“ˆ Bank of America and Barclays increased their price targets in early 2026, citing upside from biosimilars and new business lines.

πŸš€ William Blair initiated coverage with a bullish stance in April 2026, highlighting McKesson's strong execution in healthcare distribution.

πŸ“‰ Several major analysts including Evercore ISI trimmed targets in April 2026 due to cautious assumptions on valuation and execution risk.

⚠️ Evercore ISI specifically placed McKesson on its "Tactical Underperform" list focusing on short-term concerns.

πŸ’° McKesson repurchased 2.5 million shares worth US$2.69 billion between January and March 2026, totaling 43.79% of outstanding shares.

πŸ“œ The company increased equity repurchase authorization by US$5 billion, bringing the total approved to US$29 billion.

πŸ‘” CFO Britt Vitalone is retiring after 20 years and will transition to a strategic advisor role while Kenny Cheung steps in as new CFO.

πŸ“Š Revenue growth assumptions in the fair value model were lowered from 8.12% to 7.37%.

πŸ’Ό Net profit margin assumptions were slightly improved from 1.19% to 1.21% in the updated valuation model.

πŸ” Future P/E multiple assumptions were reduced from 23.04x to 20.49x reflecting a shift in valuation outlook.

⚠️ Discount rate assumptions were adjusted upward from 6.98% to 7.11% to reflect higher risk considerations.

πŸ”¬ Key long-term narratives include expansion into specialty pharmaceuticals and investments in automation and digitization.

πŸ’Š Investors face risks related to drug pricing pressure, vertical integration by manufacturers, and lower margin generics.

Bullish Signals
  • BofA and Barclays both lifted their McKesson targets in early 2026, with BofA moving to US$1,040 and Barclays to US$1,050, signaling that some firms see room above the current fair value estimate.
  • BofA highlights potential upside from biosimilars, including McKesson's National Drug Code for a biosimilar version of Neulasta and the prospect of seven large biosimilars coming to market over the next few years.
  • William Blair initiated coverage with a bullish stance in April 2026, suggesting confidence in McKesson's execution and positioning within healthcare distribution and related services.
  • From January 1, 2026 to March 31, 2026, McKesson repurchased 2,500,000 shares for US$2,695.61m, demonstrating commitment to shareholder returns and confidence in its stock valuation.
  • On April 29, 2026, McKesson increased its equity repurchase authorization by US$5,000m, taking the total approved amount to US$29,000m, providing ample firepower for continued buybacks.
  • McKesson's net profit margin assumption improved slightly from 1.19% to 1.21%, indicating potential margin expansion despite revenue growth rate adjustments.
  • The transition to CFO Kenny Cheung brings experienced leadership with a background at Sysco, enhancing McKesson's capability in foodservice and distribution expertise.
  • Future P/E multiple remains elevated at 23.04x pre-adjustment, reflecting the market's recognition of McKesson's long-term earnings growth potential.
Risk Factors
  • Fair value estimate was trimmed by 4% from US$990.87 to US$951.73 in the latest model update, reflecting reduced analyst confidence.
  • Revenue growth assumptions were downgraded from 8.12% to 7.37%, indicating slower than previously expected expansion.
  • Future P/E multiple was lowered from 23.04x to 20.49x, suggesting a lower valuation premium relative to peers.
  • Multiple analysts including BofA, JPMorgan, Deutsche Bank, Baird, UBS, Wells Fargo and Evercore ISI have recently trimmed price targets, citing cautious assumptions around valuation or execution risk.
  • Evercore ISI specifically placed McKesson on a 'Tactical Underperform' list due to shorter term concerns investors may weigh against the long-term growth story.
  • The CFO Britt Vitalone is retiring after 20 years, creating a transition risk at Executive Vice President and CFO level with Kenny Cheung joining from Sysco effective May 29, 2026.
  • Key risks identified include drug pricing pressure, vertical integration by manufacturers and payers, lower margin generics, and shifts in healthcare access and technology.
Full Analysis
McKesson's (MCK) valuation outlook has become mixed as analysts diverge on its risk-reward profile following a reduction in Simply Wall St's fair value estimate from US$990.87 to US$951.73, representing a 4% decrease. This adjustment aligns with a shifting landscape where bullish banks like Bank of America lifted targets to US$1,040 and Barclays set US$1,050 in early 2026, citing upside potential from biosimilars such as the National Drug Code for Neulasta, while other firms including JPMorgan and Wells Fargo trimmed targets due to cautious valuation assumptions. William Blair initiated coverage with a bullish stance in April 2026, highlighting confidence in McKesson's execution within healthcare distribution, whereas Evercore ISI placed the stock on its "Tactical Underperform" list following an April target cut, signaling short-term concerns about execution risks that investors may weigh against long-term growth. Financial and operational developments further define the current narrative, with McKesson repurchasing 2,500,000 shares between January 1, 2026, and March 31, 2026, for US$2.7 billion to reduce its outstanding share count by approximately 2.03%. The company also increased its total equity repurchase authorization to US$29 billion following a US$5 billion boost on April 29, 2026. Leadership transitions are underway as CFO Britt Vitalone retires after a two-decade career with plans for him to remain as a strategic advisor during the separation of the Medical Surgical Solutions business, while Kenny Cheung from Sysco assumes the CFO role effective May 29, 2026. Simply Wall St updated its fair value model assumptions reflecting these broader market dynamics, adjusting revenue growth expectations down to 7.37% from 8.12%, slightly improving net profit margin forecasts to 1.21% from 1.19%, and lowering the future P/E multiple projection to 20.49x from 23.04x while raising the discount rate to 7.11%. The analysis underscores ongoing strategic narratives regarding expansion into specialty pharmaceuticals, oncology drugs, and value-added services that influence revenue mix, alongside investments in automation and digitization intended to drive long-term efficiency. Key risks remain centered on drug pricing pressure, vertical integration by manufacturers, margin compression from generic shifts, and evolving healthcare access technologies, as the stock continues to balance short-term tactical warnings with its broader long-term growth story in healthcare distribution.